Topline Clinical Results

Kodiak Shares Climb Following Positive Results From Late-Stage Retina Disease Study

Kodiak Sciences Inc. (NASDAQ: KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion.

DBV Technologies' Shares Shoot Higher As Positive Results From Late-Stage Study Of Peanut Allergy In Toddlers Met Primary Endpoint

DBV Technologies (NASDAQ: DBVT) announced positive topline results from EPITOPE study of its drug candidate Viaskin Peanut 250 µg for the treatment of peanut-allergic toddlers ages 1 to 3 years.